Key Points
- Insider sale: Pharvaris insider Anna Nijdam sold 2,670 shares on June 4 at an average price of $30.87, totaling $82,422.90. After the transaction, she still held 46,275 shares, and the sale reduced her position by 5.46%.
- Recent insider activity: Nijdam also sold shares on May 21 and May 22, including 1,829 shares for $55,967.40 and 5,501 shares for $169,100.74. The article highlights a series of recent insider disposals rather than a single isolated trade.
- Company and analyst snapshot: Pharvaris stock was up 1.6% and traded at $31.59, near its 52-week high of $33.33. Analysts remain mostly positive, with an average rating of Moderate Buy and a consensus price target of $49.18, despite the company still reporting losses.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) insider Anna Nijdam sold 2,670 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the sale, the insider owned 46,275 shares of the company's stock, valued at $1,428,509.25. This trade represents a 5.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Anna Nijdam also recently made the following trade(s):
- On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total value of $55,967.40.
- On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total value of $169,100.74.
Pharvaris Trading Up 1.6%
PHVS opened at $31.59 on Tuesday. Pharvaris N.V. has a 1-year low of $16.00 and a 1-year high of $33.33. The stock has a market capitalization of $2.07 billion, a PE ratio of -9.93 and a beta of -2.35. The firm has a 50-day moving average price of $29.32 and a two-hundred day moving average price of $27.37.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.82) by $0.12. On average, research analysts predict that Pharvaris N.V. will post -3.22 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of PHVS. GF Fund Management CO. LTD. bought a new stake in Pharvaris in the fourth quarter valued at approximately $35,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Pharvaris during the third quarter worth $75,000. Barclays PLC acquired a new position in shares of Pharvaris in the 4th quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Pharvaris in the 4th quarter valued at $86,000.
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research note on Tuesday, April 21st. Royal Bank Of Canada lowered their price target on shares of Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research report on Monday, April 6th. Wedbush increased their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an "outperform" rating in a report on Tuesday, April 7th. Wall Street Zen raised shares of Pharvaris from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Citigroup reaffirmed a "buy" rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $49.18.
Get Our Latest Research Report on Pharvaris
About Pharvaris
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
